Navigation Links
Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
Date:3/9/2009

SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2008 financial results and provide a general business update on Monday, March 16, 2009, at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2008 will be released after markets close on March 16, 2009.

Interested parties may call 877-718-5104 from the U.S. or +1-719-325-4794 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
2. Medivation Announces Participation in Upcoming Conferences
3. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
6. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
7. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
8. National Western Life Announces 2008 Fourth Quarter and 2008 Earnings
9. Celebrity Chef Cat Cora Announces First Pregnancy
10. National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors
11. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... North Carolina have remained steady since 2009, according to a Workers Compensation Research ... The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due to months of ... call for diligence, asking homeowners to scout for any open water sources that can ... the annoying buzz of mosquitos is the buzz associated with potential infections stemming from ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has announced ... laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools participants ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 2017 Radiology has become the number one ... also spiraled to the number one ranking as a ... ever before as the most complete and reliable method ... lower back pain an MRI may confirm a suspected ... resulting in entirely different treatment protocols.  In these circumstances, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
Breaking Medicine Technology: